Pfizer-BioNTech

Request correction

Product brand

Unclaimed Read 2× by AI crawlers

A jointly developed mRNA COVID-19 vaccine marketed internationally as Comirnaty by Pfizer and BioNTech.

Last updated November 4, 2026

AI crawler reads

2requests

1companies

Anthropic2

Profile: 2
Controversies: 0
JSON · MD: 0

First read: Nov 4, 2026
Latest read: Nov 4, 2026

From this site's server log

Overview

Pfizer-BioNTech is the commonly used partnership and product designation for the mRNA COVID-19 vaccine developed by BioNTech and Pfizer. BioNTech, a German biotechnology company founded in Mainz in 2008 by Uğur Şahin, Özlem Türeci, and Christoph Huber, supplied the underlying messenger-RNA technology and led important elements of the vaccine research program. Pfizer contributed large-scale clinical-development capabilities, regulatory expertise, manufacturing capacity, supply-chain coordination, and international commercialization. The collaboration became one of the most consequential pharmaceutical partnerships of the COVID-19 pandemic. The relationship developed from an earlier 2018 agreement between Pfizer and BioNTech covering mRNA-based influenza research. When the novel coronavirus emerged in early 2020, the companies expanded their cooperation to a SARS-CoV-2 vaccine program. BioNTech's candidate, initially identified as BNT162b2 and later branded Comirnaty, uses lipid nanoparticles to deliver messenger RNA encoding the virus's spike protein. The approach instructs cells to produce a temporary antigen, enabling the immune system to develop a response without using a live virus. The vaccine achieved a major scientific and regulatory milestone in November 2020, when an interim analysis from its pivotal clinical trial indicated high efficacy against symptomatic COVID-19. The United Kingdom granted the first emergency authorization for the vaccine in December 2020, followed shortly afterward by emergency or conditional authorizations in other jurisdictions, including the United States and the European Union. The United States later granted full approval to Comirnaty for specified age groups in August 2021. Subsequent versions were updated to address changing SARS-CoV-2 variants and evolving public-health recommendations. Pfizer-BioNTech became a global household name through the scale of its rollout. Governments, health systems, pharmacies, and international distribution partners used the product in primary vaccination campaigns and later booster programs. Marketing and public-education activity expanded after regulatory approval permitted direct-to-consumer promotion in the United States. Pfizer used television, digital media, sports programming, institutional communications, and a 2022 Marvel collaboration to encourage vaccination and booster uptake. The companies also participated in broader efforts to address vaccine hesitancy and reach communities disproportionately affected by the pandemic. The brand is not a standalone corporation. It represents a commercial and scientific collaboration between Pfizer and BioNTech, while Comirnaty is the principal product name used in many markets. BioNTech retains a strategic focus on mRNA technology and oncology, whereas Pfizer operates a diversified biopharmaceutical business spanning vaccines, oncology, inflammation and immunology, internal medicine, and other therapeutic areas. After the exceptional pandemic demand period, both companies faced a substantially more commercialized COVID-19 market, changing booster recommendations, lower purchasing volumes, and continuing competition from other vaccine manufacturers. The partnership nevertheless remains associated with rapid vaccine development, mRNA commercialization, and the transformation of pandemic biomedical research into a globally distributed product.

History

Pfizer-BioNTech emerged from the convergence of Pfizer's global pharmaceutical infrastructure and BioNTech's mRNA research platform. Pfizer was founded in New York in 1849 by Charles Pfizer and Charles F. Erhart and developed into a multinational pharmaceutical company. BioNTech was established in Mainz in 2008 by physician-scientists Uğur Şahin, Özlem Türeci, and Christoph Huber, with a mission centered on individualized cancer medicine, immunotherapy, and emerging messenger-RNA technologies. The companies began collaborating before the COVID-19 pandemic. In 2018, Pfizer and BioNTech signed an agreement to research and develop mRNA-based influenza vaccines. The arrangement gave Pfizer access to BioNTech's platform while allowing BioNTech to draw on Pfizer's development, regulatory, manufacturing, and commercialization capabilities. The partnership was broadened in 2020 when the emergence of SARS-CoV-2 created an urgent need for a vaccine. BioNTech rapidly selected and advanced several vaccine candidates under the BNT162 program. The eventual lead candidate, BNT162b2, uses nucleoside-modified messenger RNA packaged in lipid nanoparticles. Pfizer supported clinical development and prepared the operational system required for a global rollout. The companies' pivotal trial enrolled tens of thousands of participants across multiple countries. In November 2020, they reported interim results showing high protection against symptomatic disease, creating a decisive moment in the global vaccine race. Regulatory authorization followed at unprecedented speed. The United Kingdom authorized the vaccine for emergency use in December 2020, and the United States Food and Drug Administration issued an emergency-use authorization shortly afterward. The European Union and numerous other jurisdictions also authorized the product. It was marketed under the name Comirnaty, while public discourse frequently referred to it as the Pfizer vaccine or the Pfizer-BioNTech vaccine. The product became a central component of national vaccination programs and was administered at very large scale. The vaccine's development and rollout reshaped both companies. Pfizer became more closely associated with mRNA technology and pandemic response, while BioNTech gained global visibility as an independent biotechnology innovator. The companies subsequently developed and sought authorization for updated formulations addressing new variants, including Omicron-related strains. Recommendations evolved from primary vaccination schedules toward periodic booster programs as immunity, variants, age groups, and public-health guidance changed. Commercial communication also changed over time. During the initial emergency-authorization period, direct-to-consumer promotion in the United States was restricted. After full approval of Comirnaty in 2021, Pfizer began more visible consumer advertising, including television campaigns and placements around major sports programming. In 2022, Pfizer and BioNTech worked with Marvel on an educational comic intended to make booster messaging more accessible. These efforts complemented government and nonprofit vaccine-information campaigns that addressed access, confidence, and historically rooted distrust. The partnership entered a different phase after the acute pandemic period. Government purchasing declined as vaccination moved toward routine commercial channels, and demand for COVID-19 products fell from its extraordinary peak. Pfizer's wider corporate strategy shifted toward rebuilding growth through oncology, specialty medicines, licensing, and portfolio changes, while BioNTech continued investing heavily in oncology and mRNA applications. Even as the market matured, Pfizer-BioNTech remained a defining case of cross-border biomedical collaboration, platform technology deployment, and rapid vaccine industrialization.

2023
Updated booster recommendations
[6]CDC panel approves revised COVID-19 vaccinepbs.org
U.S. public-health authorities approve revised COVID-19 vaccination recommendations and updated products.
2022
Marvel booster campaign launches
[4]Pfizer and BioNTech enlist Marvel in booster campaignfiercepharma.com
Pfizer and BioNTech release the Everyday Heroes comic with Marvel as part of a booster-awareness effort.
2021
Comirnaty receives full U.S. approval
[3]Pfizer kicks off major Comirnaty COVID vaccine ad campaignfiercepharma.com
The FDA grants full approval for specified age groups, marking a transition beyond emergency-use status in the United States.
2020
SARS-CoV-2 vaccine program begins
[5]Companies submit COVID-19 vaccine to FDApbs.org
Pfizer and BioNTech broaden their cooperation to develop a vaccine against COVID-19.
2020
BNT162b2 demonstrates high efficacy
[7]BNT162b2 demonstrates high efficacyforbes.com
Interim pivotal-trial findings indicate strong efficacy against symptomatic COVID-19 for the candidate that becomes Comirnaty.
2020
First emergency authorizations
[5]Companies submit COVID-19 vaccine to FDApbs.org
The vaccine receives initial emergency or conditional authorizations, beginning with the United Kingdom and followed by other major markets.
2018
Pfizer and BioNTech begin mRNA collaboration
[1]Pfizeren.wikipedia.org
The companies agree to collaborate on mRNA-based influenza vaccine research, establishing the relationship later expanded for COVID-19.

Products and positioning

A science-led, globally distributed mRNA vaccine partnership positioned around rapid innovation, clinical evidence, public-health protection, and trusted pharmaceutical-scale manufacturing.

mRNA COVID-19 vaccine · 2020
Comirnaty
Comirnaty is the commercial name for the Pfizer-BioNTech COVID-19 vaccine. It is based on nucleoside-modified messenger RNA delivered in lipid nanoparticles. The mRNA encodes the SARS-CoV-2 spike protein, prompting an immune response without introducing live virus. The product was initially deployed under emergency or conditional authorizations in 2020 and later received full approval in the United States for specified age groups. Updated formulations have been developed as the virus and vaccination recommendations changed.

Controversies

2022
Alnylam sues Moderna and Pfizer over lipid patent
Alnylam filed lawsuits against Moderna and Pfizer in federal court in Delaware, alleging that their COVID-19 vaccines infringe its biodegradable-lipids patent. Alnylam said it was seeking monetary relief and did not want to impede vaccine sales, production or distribution. Moderna denied the allegation; Pfizer had not commented to the outlet.
Source

2022Everyday Heroes
United States
Pfizer, BioNTech, and Marvel created a custom Avengers-themed comic to encourage people to stay current with COVID-19 booster vaccination.
Outcome. The initiative used popular entertainment characters to make booster education more culturally accessible as vaccination moved toward a commercial market.
Source
2021Remarkable
United States
Pfizer's early Comirnaty television advertising emphasized the desire to return to ordinary social life and the company's scientific mission rather than relying solely on direct product claims.
Outcome. The campaign represented Pfizer's move toward more visible consumer communication after regulatory approval.
Source
2020Science Will Win
Global
Pfizer used the Science Will Win platform to communicate confidence in scientific research and vaccine development during the pandemic.
Outcome. The campaign helped associate Pfizer's corporate identity with scientific progress and the COVID-19 response.
Source

Brand decisions

2021
Move Comirnaty into full-approval-era commercializationProduct launch
Background
Full U.S. approval created a regulatory basis for broader commercial promotion beyond the restrictions associated with emergency authorization.
Action taken
Pfizer increased direct-to-consumer advertising and promoted Comirnaty through television and sports-media placements.
Aftermath
The vaccine became more visibly marketed as a branded pharmaceutical product while remaining part of public-health vaccination programs.
- Moderna — Moderna also increased attention to booster-season communication and competed for COVID-19 vaccine demand.
Source
2020
Expand the influenza mRNA partnership into COVID-19 vaccine developmentStrategy
Background
The emergence of SARS-CoV-2 created an urgent global need for a vaccine, while BioNTech already had an mRNA platform and Pfizer had large-scale development and manufacturing capabilities.
Action taken
Pfizer and BioNTech broadened their existing collaboration to develop, test, seek authorization for, and distribute an mRNA COVID-19 vaccine.
Aftermath
The resulting program produced Comirnaty, one of the first widely authorized COVID-19 vaccines and a major global vaccine product.
- Moderna — Moderna pursued its own mRNA COVID-19 vaccine and competed with Pfizer-BioNTech for public procurement, booster demand, and later commercial-market share.
Source

Recent events

2022.03.17
Reported2022.03.17
Alnylam sues Moderna and Pfizer over lipid patent[9]Alnylam sues Moderna and Pfizer over lipid patentmedcitynews.com
Alnylam filed lawsuits against Moderna and Pfizer in federal court in Delaware, alleging that their COVID-19 vaccines infringe its biodegradable-lipids patent. Alnylam said it was seeking monetary relief and did not want to impede vaccine sales, production or distribution. Moderna denied the allegation; Pfizer had not commented to the outlet.
2021.09.22
Reported2021.09.24
FDA authorizes Pfizer-BioNTech COVID-19 vaccine booster for certain populations[10]FDA授权特定人群接种辉瑞-BioNTech新冠疫苗加强针republicworld.com
The FDA amended the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine to allow a single booster dose, at least six months after completion of the primary series, for certain populations.
2021.09.22
Reported2021.09.23
FDA authorizes limited Pfizer-BioNTech booster shots[11]FDA授权辉瑞-BioNTech有限人群加强针newsweek.com
The FDA approved Pfizer/BioNTech COVID-19 booster shots for certain eligible populations, including people aged 65 and older at least six months after their second dose.
2021.05.10
Reported2021.05.10
FDA expands Pfizer-BioNTech vaccine authorization to adolescents[12]FDA扩大辉瑞-BioNTech疫苗紧急使用授权至青少年1031theticket.com
The FDA expanded the emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine to include adolescents aged 12 through 15.
2020.12.14
Reported2020.12.14
Singapore signs advance-purchase agreements with three vaccine makers[13]新加坡与三家疫苗生产商签订预先采购协议tech.sina.com.cn
Singapore signed advance-purchase agreements with Moderna, Pfizer-BioNTech and Sinovac for COVID-19 vaccines. The report said the first Pfizer vaccine batch was due to arrive by the end of December, with the other companies' vaccines expected to arrive the following year.

Sources18 sources

Cite this profile: Cite the canonical profile. /brand-wiki/pfizer-biontech · Editorial policy · How profiles are compiled